Skip to content
FIND A BIOALPS ACTOR
Helvetica Health Care

COVID-19 Testimonial Series | Helvetica Health Care

09.09.2020
Share this article

Marketing and distribution of a wide range of molecular controls and panels

 

The following article is part of BioAlps’ testimonial series and was written by Mr Michael Moore, Director of Marketing and Sales at Helvetica Healthcare Sàrl. Our series aims to provide a platform for the different life sciences actors from western Switzerland, who are active in finding and developing solutions to fight against the new coronavirus, to share their experience. 

 

Presentation of HHC’s COVID-19 related activities

Helvetica Health Care markets and distributes a wide range of molecular controls and panels, including many for COVID-19, SARS and influenza.

The aim of Helvetica Health Care has always been to keep products close to the customers, to ensure rapid and safe delivery.

Accurately forecasting stock requirements is difficult at the best of times, and clearly almost impossible during a pandemic. However, stock of COVID-19 related products has been maintained in our Geneva warehouse, located at the airport, from where we can ship very quickly to our Swiss customers, as well as anywhere in Europe and the rest of the world.

This has enabled our customers to receive the products they need, when they need them. Our customers are primarily Pharmaceutical and Diagnostic companies working on developing either vaccines or COVID-19 related testing products, as well as laboratories performing molecular testing on patient samples. We are aware of how important efficient delivery of these products is to support the fight against COVID, and our team is committed to providing unrivalled service and support.

 

Exogenous impact of COVID-19 on the company

The pandemic has resulted in a significant increase in sales this year, though it is clear that some sectors have slowed significantly, particularly in the early stages of the pandemic. Fortunately, extra sales from COVID-19 have more than replaced this deficit.

Due to the high profile of COVID-19, the company has experienced an increased level of visibility. Relationships with some key supply partners has been strained due to closure of airports, staff shortages within the transport sector and breakdown of information systems.

Relationships with customers and new service providers have strengthened. Our team has always gone the extra mile to get product to the customers, so we have explored new methods and options. This has cemented our relationships with many customers and partners.

Helvetica Health Care should continue its growth following COVID-19, but it is likely that changes made as part of the survival process during the pandemic, will be implemented longer term.

 

Endogenous impact of COVID-19 on the company

Remote working has become the norm for most staff. While this can create difficulties in management, it seems to have increased productivity short term as staff tend to work longer, with more flexible hours. There is concern however regarding the impact on morale, team working and staff psychology longer term.

It is likely that remote working, smaller office space and the new service providers will be maintained after COVID-19.